Results 81 to 90 of about 1,273,410 (345)

Publisher Correction: Interplay between hypoxia and androgen controls a metabolic switch conferring resistance to androgen/AR-targeted therapy

Nature Communications, 2019
The original version of this Article contained errors in Fig. 7. In panels e and f, the graph titles incorrectly read ‘LNCaP-AdtNs’ and ‘LAPC4-AdtNs’, respectively. These errors have now been corrected in both the PDF and HTML versions of the Article.
Hao Geng, Changhui Xue, Janet Mendonca, Xiao-Xin Sun, Qiong Liu, Patrick N. Reardon, Yingxiao Chen, Kendrick Qian, Vivian Hua, Alice Chen, Freddy Pan, Julia Yuan, Sang Dang, Tomasz M. Beer, Mu-Shui Dai, Sushant K. Kachhap, David Z. Qian   +16 more
doaj   +1 more source

Chemosensitization of Human Renal Cell Cancer Using Antisense Oligonucleotides Targeting the Antiapoptotic Gene Clusterin

Neoplasia: An International Journal for Oncology Research, 2001
BACKGROUND: Renal cell cancer (RCC) is a chemoresistant disease with no active chemotherapeutic agent achieving objective response rates higher than 15%.
Tobias Zellweger, Hideaki Miyake, Laura V. July, Majid Akbari, Satoshi Kiyama, Martin E. Gleave   +5 more
doaj   +1 more source

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.

New England Journal of Medicine, 2015
BACKGROUND Prostate cancer is a heterogeneous disease, but current treatments are not based on molecular stratification. We hypothesized that metastatic, castration-resistant prostate cancers with DNA-repair defects would respond to poly(adenosine ...
J. Mateo, S. Carreira, S. Sandhu, S. Miranda, H. Mossop, R. Pérez-López, Daniel Nava Rodrigues, D. Robinson, A. Omlin, N. Tunariu, G. Boysen, N. Porta, P. Flohr, Alexa Gillman, I. Figueiredo, C. Paulding, G. Seed, Suneil Jain, C. Ralph, A. Protheroe, S. Hussain, Robert J. Jones, T. Elliott, U. McGovern, D. Bianchini, J. Goodall, Z. Zafeiriou, C. Williamson, R. Ferraldeschi, R. Riisnaes, Bernardette Ebbs, Gemma Fowler, D. Roda, W. Yuan, Yi-Mi Wu, Xuhong Cao, R. Brough, H. Pemberton, R. A’Hern, A. Swain, L. Kunju, R. Eeles, G. Attard, C. Lord, A. Ashworth, M. Rubin, K. Knudsen, F. Feng, A. Chinnaiyan, E. Hall, J. D. de Bono   +50 more
semanticscholar   +1 more source

BMP antagonist CHRDL2 enhances the cancer stem‐cell phenotype and increases chemotherapy resistance in colorectal cancer

Molecular Oncology, EarlyView.
Overexpression of CHRDL2 in colon cancer cells makes them more stem‐like and resistant to chemo‐ and radiotherapy. CHRDL2‐high cells have upregulation of the WNT pathway, genes involved in the DNA damage response (DDR) pathway and epithelial‐to‐mesenchymal transition (EMT). This leads to quicker repair of damaged DNA and more cell migration.
Eloise Clarkson, Annabelle Lewis
wiley   +1 more source

Racial/Ethnic Patterns in Prostate Cancer Outcomes in an Active Surveillance Cohort

Prostate Cancer, 2011
Introduction. Concern regarding overtreatment of prostate cancer (CaP) is leading to increased attention on active surveillance (AS). This study examined CaP survivors on AS and compared secondary treatment patterns and overall survival by race/ethnicity.
Jennifer Cullen, Stephen A. Brassell, Yongmei Chen, Christopher Porter, James L'Esperance, Timothy Brand, David G. McLeod   +6 more
doaj   +1 more source

Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade

JAMA Oncology, 2019
Importance The anti–programmed cell death protein 1 (PD-1) antibody pembrolizumab is approved by the US Food and Drug Administration for the treatment of microsatellite instability–high (MSI-H) or mismatch repair–deficient (dMMR) solid tumors, but the ...
W. Abida, M. Cheng, J. Armenia, S. Middha, K. Autio, H. Vargas, D. Rathkopf, M. Morris, D. Danila, S. Slovin, E. Carbone, E. Barnett, Melanie A. Hullings, J. Hechtman, A. Zehir, J. Shia, P. Jonsson, Z. Stadler, P. Srinivasan, V. Laudone, V. Reuter, J. Wolchok, N. Socci, B. Taylor, M. Berger, P. Kantoff, C. Sawyers, N. Schultz, D. Solit, A. Gopalan, H. Scher   +30 more
semanticscholar   +1 more source

Simultaneous inhibition of TRIM24 and TRIM28 sensitises prostate cancer cells to antiandrogen therapy, decreasing VEGF signalling and angiogenesis

Molecular Oncology, EarlyView.
TRIM24 and TRIM28 are androgen receptor (AR) coregulators which exhibit increased expression with cancer progression. Both TRIM24 and TRIM28 combine to influence the response of castrate‐resistant prostate cancer (CRPC) cells to AR inhibitors by mediating AR signalling, regulation of MYC and upregulating VEGF to promote angiogenesis. Castrate‐resistant
Damien A. Leach, Nilesh Chatterjee, Kellie Spahr, Gilberto Serrano de Almeida, Anabel Varela‐Carver, Taimur T. Shah, Mathias Winkler, Hashim U. Ahmed, Charlotte L. Bevan   +8 more
wiley   +1 more source

Tumor-associated long non-coding RNAs show variable expression across diffuse gliomas and effect on cell growth upon silencing in glioblastoma

Scientific Reports
Long noncoding RNAs (lncRNAs) have been recently recognized as critical components of cancer biology linked to oncogenic processes. Certain lncRNAs are known to act as oncogenes, and the disease-specific expression of many lncRNAs makes them informative ...
Joonas Uusi-Mäkelä, Maria Kauppinen, Janne Seppälä, Serafiina Jaatinen, Birgitta Ryback, Tommi Rantapero, Alejandra Rodriguez-Martinez, Matti Nykter, Kirsi J. Rautajoki   +8 more
doaj   +1 more source

Gold nanoshell-localized photothermal ablation of prostate tumors in a clinical pilot device study

Proceedings of the National Academy of Sciences of the United States of America, 2019
Significance Prostate cancer is the most common nonskin cancer in the United States, where approximately 1 in 9 men will be diagnosed in their lifetime.
A. Rastinehad, H. Anastos, E. Wajswol, J. Winoker, J. Sfakianos, S. Doppalapudi, M. Carrick, C. Knauer, B. Taouli, S. Lewis, A. Tewari, J. Schwartz, S. Canfield, A. George, J. West, N. Halas   +15 more
semanticscholar   +1 more source

EMT‐associated bias in the Parsortix® system observed with pancreatic cancer cell lines

Molecular Oncology, EarlyView.
The Parsortix® system was tested for CTC enrichment using pancreatic cancer cell lines with different EMT phenotypes. Spike‐in experiments showed lower recovery of mesenchymal‐like cells. This was confirmed with an EMT‐inducible breast cancer cell line.
Nele Vandenbussche, Renske Imschoot, Béatrice Lintermans, Lode Denolf, Joachim Taminau, Charlotte Fieuws, Geert Berx, Kris Gevaert, Kathleen B. M. Claes   +8 more
wiley   +1 more source